Hollow-Fiber Bioreactor Patents: Who Leads, Where the Gaps Are 2026
Hollow-Fiber Bioreactor Vessel Design Patents: Filing Trends and Leaders
Concentrated at the top. The top 5 assignees hold 42.2% of all 223 records in scope, and the top 10 hold 65.5% — vessel geometry and port-layout claims sit on a short list of repeat filers. Annual filings climbed from 6 in 2017 toward a peak of 22 in 2023, then fell — 15 in 2021 to 7 in 2024, a 53% decline over that three-year window. Treat 2025 and 2026 counts as provisional; they will revise upward as publications catch up with filing dates.
- 1GENZYME CORP23
- 2UNIVERCELLS SA20
- 3VANDERBILT UNIV19
- 4RADISIC MILICA18
- 5AMGEN INC14
See the full hollow-fiber bioreactor vessel design analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Frequently asked questions
Who holds the most patents in hollow-fiber bioreactor vessel design?
The dataset’s leading assignee holds 23 of the 223 records in scope, well ahead of the fifth-place holder at 14 and the tenth-place holder at 9. The ranking covers 83 assignees in total, and the top 10 combined account for 65.5% of all records, so filing activity is concentrated among a relatively small group of repeat filers rather than spread evenly. Anyone assessing freedom-to-operate in this space should start with that top group’s granted claims before looking at the long tail below rank 10.
Is patent filing in this field growing or shrinking?
Filings rose from 6 in 2017 to a peak of 22 in 2023, then declined from 15 in 2021 to 7 in 2024, a 53% drop over that three-year window. Because publication typically lags filing by around 18 months, the 2025 and 2026 figures in any dataset are still incomplete and should not be read as confirming a continued decline. Based on the complete years through 2024, the field has cooled from its 2023 peak but remains active.
What patent classes cover hollow-fiber and perfusion bioreactor vessel design?
The core class is C12M (bioreactors and enzyme apparatus), appearing on 98.7% of the 223 records in this landscape. C12N (microorganisms and genetic engineering) is the largest secondary class at 50.7%, reflecting that many vessel-design claims are tied to a specific cell or organism type. Smaller classes — B01L, C07K, A61K, A23L, C12P and G01N — each cover between 6.3% and 9.4% of records and mark adjacent application areas such as lab apparatus, protein products, food and analytical testing.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Hollow-Fiber Bioreactor Vessel Design covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.